| Â | Â | Greenland | Warsaw | Sweden | Kharkiv | ALL*4
| All study group data*5
|
|---|
XER*
1
RLU/ml serum
| N | 72 | 98 | 100 | 88 | 358 | 0.003 |
| Â |
Median
|
2.89
|
3.09
|
3.04
|
3.15
|
3.05
| Â |
| Â |
Mean
|
2.92
|
3.30
|
3.22
|
3.17
|
3.17
| Â |
| Â |
Min
|
1.0
|
2.4
|
2.4
|
1.0
|
1.1
| Â |
| Â |
Max
|
6.0
|
6.5
|
12
|
8.0
|
12
| Â |
| Â |
% agonist
|
1
|
21
|
12
|
14
|
-
| Â |
| Â |
% antagonist
|
35
|
5
|
12
|
17
|
-
| Â |
XER-EEQ pg/g lipid*
2
| N | 1♣
| 21 | 10 | 11 | 43 | 0.63 |
| Â |
Median
| - |
103
|
76♥
|
139
|
114
| Â |
| Â |
Mean
| - |
166
|
161
|
179
|
171
| Â |
| Â |
Min
| - |
44
|
50
|
80
|
44
| Â |
| Â |
Max
| - |
516
|
364
|
580
|
580
| Â |
XER comp*
3
RLU/ml serum
| N | 72 | 94 | 94 | 88 | 348 | < 0.001 |
| Â |
Median
|
2.65
|
2.96
|
2.90
|
2.88
|
2.86
| Â |
| Â |
Mean
|
2.69
|
3.29
|
2.89
|
2.87
|
2.95
| Â |
| Â |
Min
|
2.0
|
1.8
|
1.0
|
1.1
|
1.0
| Â |
| Â |
Max
|
3.8
|
7.0
|
6.8
|
4.5
|
7.0
| Â |
| Â |
% add/syn
|
1
|
13
|
3
|
1
|
-
| Â |
| Â |
% antagonist
|
71
|
7
|
19
|
30
|
-
| Â |
CB-153 ng/g lipid
| N | 74 | 100 | 98 | 82 | 354 | < 0.001 |
| Â |
Median
|
220
|
16
|
210
|
47
|
79
| Â |
| Â |
Min
|
5.1
|
33
|
4.1
|
5.5
|
3.3
| Â |
| Â |
Max
|
5500
|
130
|
1500
|
200
|
5500
| Â |
DDE ng/g lipid
| N | 74 | 100 | 98 | 82 | 354 | < 0.001 |
| Â |
Median
|
630
|
570
|
240
|
880
|
560
| Â |
| Â |
Min
|
66
|
240
|
55
|
324
|
55
| Â |
| Â |
Max
|
13000
|
2100
|
2300
|
12000
|
13000
| Â |
- In the independent assays significant differences between the triple serum extract determinations and their respective solvent controls (% agonists/additive/synergistic) and % antagonists, were tested by the Student's t-test (Microsoft Office Excel, significance level p = 0.05). *1: XER: Xenoestrogenic agonistic or antagonistic activity of serum extract alone: the solvent control = 3.13 RLU/ml serum. % agonistic and % antagonistic indicates the % of samples eliciting a significantly increase or decrease in XER activity compared to solvent control, which was set to 1. *2: XER-estradiol equivalence (XER-EEQ) of the samples eliciting significantly agonistic activity; data calculated by interpolation to the E2 dose response curve using the sigma plot program. ♥ : One Swedish sample was too high to calculate the XER-EEQ. ♣ : One serum sample from Greenland only had an agonistic action, thus no XER-EEQ value is given. *3: XERcomp; XER competitive activity of serum extract + 25 pM 17β-estradiol (E2-EC40); % add/syn: additive/synergistic and % antagonistic indicates the % of samples responding with a further increase or a decrease of the E2-EC40 induced activity, respectively, compared to the E2-EC40 solvent control = 3.13 RLU/ml serum, which was set to 1;. *4: XER activity includes 358 samples, however, only 348 of theses samples were applied to the XERcomp analyses. All of the samples had CB-153 and p,p'-DDE determined. *5: One-way ANOVA (p value) evaluation of the combined study group data except for XER-EEQ including only the European groups. In transformed data was used.
